2. Search Result
Search Result
Results for "

liver-targeted

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

3

Peptides

1

MCE Kits

3

Natural
Products

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111288
    MB-07811

    VK-2809

    		 Thyroid Hormone Receptor Metabolic Disease Endocrinology
    MB-07811 (VK-2809) is an orally active HepDirect prodrug of MB07344, a liver-targeted thyroid hormone receptor-β agonist . MB-07811 has cholesterol and triglycerides lowering activity .
    MB-07811
  • HY-153006
    2,7-Dichlorodihydrofluorescein
    Maximum Cited Publications
    8 Publications Verification

    DCFH2

    		 Biochemical Assay Reagents Others
    2,7-Dichlorodihydrofluorescein (DCFH2) is a non-fluorescent reactive oxygen species (ROS) probe with an excitation wavelength of 485-500 nm and an emission wavelength of 515-530 nm. 2,7-Dichlorodihydrofluorescein is first hydrolyzed by intracellular esterases and then oxidized by ROS to generate non-biomembrane-permeable, highly fluorescent 2,7-dichlorofluorescein (DCF). The fluorescence intensity of DCF is positively correlated with the ROS concentration. 2,7-Dichlorodihydrofluorescein can undergo oxidation reactions with a variety of ROS (such as ·OH, H2O2, ONOO -, etc.) and is used to quantitatively detect the level of oxidative stress inside and outside cells. It is suitable for oxidative stress analysis in in vitro cell models and in vivo targeted delivery (such as liver-targeted liposomes) .
    2,7-Dichlorodihydrofluorescein
  • HY-13070
    MK-8245
    4 Publications Verification

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    MK-8245 is a potent, liver-targeted stearoyl-CoA desaturase (SCD) inhibitor, with IC50s of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with antidiabetic and antidyslipidemic efficacy .
    MK-8245
  • HY-41121
    Boc-L-Ala-OH
    1 Publications Verification

    Boc-Ala-OH

    		 Amino Acid Derivatives Cancer
    Boc-L-Ala-OH (Boc-Ala-OH) is a single N-protected amino acid ligand and a protected L-alanine derivative. Boc-L-Ala-OH promotes Pd (II)-catalyzed enantioselective C-H alkenylation and kinetic resolution. Boc-L-Ala-OH serves as a coupling reagent for the synthesis of liver-targeted glycogen phosphorylase inhibitors and P6A metabolites, and also acts as a negative control in synthesis studies of betulinic acid amino acid esters. Boc-L-Ala-OH is applicable to research on epidermoid squamous cell carcinoma .
    Boc-L-Ala-OH
  • HY-N0248
    Saikosaponin B2
    2 Publications Verification

    		 HCV P-glycoprotein Infection Cancer
    Saikosaponin B2 is an antiviral and anticancer agent that regulates multiple transporters (such as various solute carriers and ATP-binding cassette transporters including MRP1, MRP2, and OCT2). Saikosaponin B2 is isolated from the plant glycoside component of the roots of Bupleurum scorzonerifolium. Saikosaponin B2 enhances the liver targeting of anticancer drugs via vinegar-baked Radix Bupleuri. Saikosaponin B2 inhibits HCV entry, replication, and translation, is effective against Daclatasvir (HY-10466)-resistant strains, and exerts a synergistic effect when used in combination with Daclatasvir. Saikosaponin B2 is commonly used in studies related to hepatocellular carcinoma and HCV infection .
    Saikosaponin B2
  • HY-147266
    Elebsiran sodium

    VIR-2218 sodium

    		 Small Interfering RNA (siRNA) HBV Infection
    Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections .
    Elebsiran sodium
  • HY-154974
    LNP Lipid-8

    		Liposome Cancer
    LNP Lipid-8 (11-A-M) is an ionizable single-tail multi-head lipid that can be used as a lipid nanoparticle (LNP) to deliver siRNA to T cells without targeting ligands. LNP Lipid-8 is more selective for T cells than other cell types such as hepatocytes. LNP Lipid-8 selectively delivers siRNA/sgRNA to T cells (especially CD8+ T cells) through endogenous lipid transport pathways, and can enter cells and release RNA through endocytosis to achieve gene silencing. LNP Lipid-8 loaded with GFP siRNA (siGFP) significantly led to GFP gene silencing in mouse models. LNP Lipid-8 showed good efficacy and safety in both cells and animals, without obvious liver targeting and toxicity. LNP Lipid-8 can be used for RNA delivery research in the fields of tumor immunotherapy and T cell-mediated autoimmune diseases .
    LNP Lipid-8
  • HY-158827A
    AZD8233 sodium

    		PCSK9 Metabolic Disease
    AZD8233 sodium, a liver-targeting antisense oligonucleotide (ASO), inhibits subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 sodium increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.
    AZD8233 sodium
  • HY-134769
    OPC-163493

    		Mitochondrial Metabolism Reactive Oxygen Species (ROS) Cardiovascular Disease Metabolic Disease
    OPC-163493 is an orally active and liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces the production of mitochondrial Δψ and ROS. OPC-163493 has anti-diabetic and lipid-lowering effects. In addition, OPC-163493 has a protective effect on cardiovascular disease .
    OPC-163493
  • HY-19513
    MB-07344

    		Thyroid Hormone Receptor Metabolic Disease Endocrinology
    MB-07344 is a potent thyroid hormone receptor (TR)-β agonist with a Ki of 2.17 nM. MB-07344 has additive cholesterol lowering activity in combination with Atorvastatin (HY-B0589) in rabbits, dogs and monkeys .
    MB-07344
  • HY-121212
    Icosabutate

    		LDLR Metabolic Disease Inflammation/Immunology
    Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis . Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent hypertriglyceridemia .
    Icosabutate
  • HY-N15829
    Cholyl-Lys-fluorescein sodium

    		Fluorescent Dye Metabolic Disease
    Cholyl-Lys-fluorescein sodium is a fluorescein-labeled bile acid analog. Cholyl-Lys-fluorescein sodium mimics the physiological hepatobiliary properties of glycocholic acid. Cholyl-Lys-fluorescein sodium is efficiently taken up by the liver and rapidly excreted into bile in intact form in rats. Cholyl-Lys-fluorescein sodium can serve as a liver function assessment agent, bile salt transport probe, and liver-targeted carrier .
    Cholyl-Lys-fluorescein sodium
  • HY-13077
    MK-8245 Trifluoroacetate
    4 Publications Verification

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    MK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.
    MK-8245 Trifluoroacetate
  • HY-147266A
    Elebsiran

    VIR-2218

    		 HBV Small Interfering RNA (siRNA) Infection
    Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections .
    Elebsiran
  • HY-W451406B
    NH2-PEG1000-NH2

    		Drug Intermediate Biochemical Assay Reagents Metabolic Disease
    NH2-PEG1000-NH2 is a double-ended amino polyethylene glycol with a number-average molecular weight of 1000, which serves as a synthetic raw material for adamantyl polyethylene glycol amine. NH2-PEG1000-NH2 can be used for the preparation of reduction-responsive liver-targeted polymeric micelles .
    NH2-PEG1000-NH2
  • HY-19513A
    MB-07344 sodium

    		Thyroid Hormone Receptor Metabolic Disease Endocrinology
    MB-07344 sodium is a potent thyroid hormone receptor (TR)-β agonist with a Ki of 2.17 nM. MB-07344 sodium has additive cholesterol lowering activity in combination with Atorvastatin (HY-B0589) in rabbits, dogs and monkeys .
    MB-07344 sodium
  • HY-138942
    PF-06427878

    		Acyltransferase Metabolic Disease Inflammation/Immunology
    PF-06427878 is an orally active, selective liver-targeted diacylglycerol acyltransferase 2 (DGAT2) inhibitor with IC50s of 99 nM and 202 nM for human and rat DGAT2, respectively. PF-06427878 shows greater than 470-fold selectivity for DGAT2 over DGAT1, MGAT1, MGAT2 and MGAT3. PF-06427878 can improve liver steatosis and function. PF-06427878 can be used for the study of nonalcoholic fatty liver diseases .
    PF-06427878
  • HY-W005729
    β-D-Galactosamine pentaacetate

    		Biochemical Assay Reagents Others
    β-D-Galactosamine pentaacetate is an intermediate in the synthesis of triantennary N-Acetylgalactosamine ligands. β-D-Galactosamine pentaacetate can be studied in liver-targeted delivery of siRNA research .
    β-D-Galactosamine pentaacetate
  • HY-158825
    Cepadacursen sodium

    CIVI007 sodium

    		 PCSK9 Metabolic Disease
    Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia research and the prevention of atherosclerotic cardiovascular disease (ASCVD).
    Cepadacursen sodium
  • HY-158827
    AZD8233

    		PCSK9 Metabolic Disease
    AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.
    AZD8233
  • HY-145649A
    Zilebesiran sodium

    AD-85481 sodium; ALN-AGT sodium

    		 Small Interfering RNA (siRNA) Asialoglycoprotein Receptor (ASGPR) Cardiovascular Disease
    Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension .
    Zilebesiran sodium
  • HY-P2548
    pp60 (v-SRC) Autophosphorylation Site, Phosphorylated

    		EGFR Others
    pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification .
    pp60 (v-SRC) Autophosphorylation Site, Phosphorylated
  • HY-178770
    (α-D-Mannopyranosyloxy)3-N3

    		Others Others
    (α-D-Mannopyranosyloxy)3-N3 is a type of N-acetylgalactosamine (GalNAc) that exhibits liver-targeting properties and can be used in the synthesis of oligonucleotides .
    (α-D-Mannopyranosyloxy)3-N3
  • HY-161647
    Antitumor agent-156

    		Reactive Oxygen Species (ROS) Apoptosis Autophagy Ferroptosis Cancer
    Antitumor agent-156 (Compound 20) causes DNA damage and mitochondrial dysfunction, promotes reactive oxygen species generation, activates endoplasmic reticulum stress, and induce apoptosis, autophagy and ferroptosis. Antitumor agent-156 shows superior antitumor activity against cancer cells including Cisplatin (HY-17394) resistance cells. Antitumor agent-156 displayS good liver-targeting ability .
    Antitumor agent-156
  • HY-N0248R
    Saikosaponin B2 (Standard)

    		Reference Standards P-glycoprotein HCV Infection Cancer
    Saikosaponin B2 (Standard) is the analytical standard of Saikosaponin B2. This product is intended for research and analytical applications. Saikosaponin B2 is an antiviral and anticancer agent that regulates multiple transporters (such as various solute carriers and ATP-binding cassette transporters including MRP1, MRP2, and OCT2). Saikosaponin B2 is isolated from the plant glycoside component of the roots of Bupleurum scorzonerifolium. Saikosaponin B2 enhances the liver targeting of anticancer drugs via vinegar-baked Radix Bupleuri. Saikosaponin B2 inhibits HCV entry, replication, and translation, is effective against Daclatasvir (HY-10466)-resistant strains, and exerts a synergistic effect when used in combination with Daclatasvir. Saikosaponin B2 is commonly used in studies related to hepatocellular carcinoma and HCV infection .
    Saikosaponin B2 (Standard)
  • HY-W1141596
    N-Acetylgalactosamine trimer

    		Drug Derivative Others
    N-Acetylgalactosamine trimer (the second structure in example 59) is a trimer of N-Acetylgalactosamine. N-Acetylgalactosamine trimer can be used for liver-targeted delivery of oligonucleotides .
    N-Acetylgalactosamine trimer
  • HY-182237
    Palmitoyl glutathione

    PGSH

    		 Liposome Metabolic Disease
    Palmitoyl glutathione (PGSH) is a palmitoylated peptide derivative and a liver-targeted liposome-forming agent. Palmitoyl glutathione can form liposome-like vesicles with cholesterol, which can encapsulate water-soluble solutes. Palmitoyl glutathione can be used in studies related to Acetaminophen (HY-66005)-induced liver necrosis .
    Palmitoyl glutathione
  • HY-182769
    TRβ agonist-4

    		Thyroid Hormone Receptor Inflammation/Immunology
    TRβ agonist-4 is an orally bioavailable, liver-targeted selective agonist of hTHR-β (EC50=6.0 nM), with a 105.3-fold selectivity over THR-α. TRβ agonist-4 exists in multiple crystal forms, including Form A, Form B, Form C, Form D, Form E, as well as an amorphous form. TRβ agonist-4 can be used for research related to non-alcoholic steatohepatitis (NASH) .
    TRβ agonist-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: